Replimune Group stock (US76029N1063): ASCO 2026 RP2 data in focus after sharp Nasdaq move

Replimune Group shares on Nasdaq are back in focus after the US biotech presented final first-in-human data for its oncolytic immunotherapy RP2 at the ASCO 2026 meeting, following an outsized price swing in recent sessions.

Replimune Group shares on the Nasdaq in the United States are drawing renewed investor attention after the Massachusetts-based biotech presented final first-in-human data for its oncolytic immunotherapy RP2 in advanced solid tumors at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, while the stock has also seen a pronounced move in recent trading.

According to the company, RP2 was evaluated as both monotherapy and in combination with nivolumab in heavily pretreated patients, with the data delivered in an oral presentation on 05/31/2026 in Woburn, Massachusetts, underscoring the scientific visibility of the program at a major US oncology conference.GlobeNewswire as of 05/31/2026

The stock, which is listed on Nasdaq under the ticker REPL, last closed at USD 8.69 on 05/29/2026, with data from a US trading platform highlighting that this level represented an increase of more than 260% over the preceding four weeks, reflecting how the market has repriced the United States biotechnology group around the ASCO catalyst.GuruFocus as of 05/31/2026 On a year-to-date basis, separate data show that the shares remain below the USD 9.72 level seen at the start of 2026, underlining lingering volatility for the clinical-stage name.MarketBeat as of 05/29/2026

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: REPL
• Sector/industry: Biotechnology, oncolytic immunotherapies
• Headquarters/country: Woburn, United States
• Core markets: United States, Europe for clinical development and future oncology commercialization
• Key revenue drivers: Pipeline of RPx oncolytic immunotherapy candidates targeting solid tumors, including RP1, RP2 and RP3, subject to successful clinical development and regulatory approvals
• Home exchange/listing venue: Nasdaq (REPL)
• Trading currency: USD

Replimune Group: core business model

Replimune Group develops next-generation oncolytic immunotherapies built on a proprietary HSV-1 platform, aiming to harness local tumor destruction to trigger systemic anti-tumor immune responses, with value creation tied primarily to advancing candidates such as RP1, RP2 and RP3 through clinical trials and ultimately into oncology markets if they secure regulatory clearance.

What banks and research houses say about Replimune Group

Publicly accessible analyst commentary on Replimune Group following the ASCO 2026 RP2 data remains limited in detailed form, but consensus snapshots from financial data providers indicate that the biotech continues to be followed by US healthcare specialists on Wall Street, with the focus on clinical catalysts and funding runway rather than near-term earnings metrics.MarketBeat as of 05/29/2026 While individual price targets and rating changes from named banks were not disclosed in free sources checked for this article, the presence of a compiled consensus underlines that the stock is still on the radar of institutional research desks that cover US mid-cap biotechnology names.

In practice, the valuation frameworks applied by these analysts tend to emphasize risk-adjusted net present value models for the RPx pipeline and scenario analyses around potential partnering or commercialization outcomes, which means that fresh clinical data such as the RP2 phase 1 readout at ASCO feed directly into their probability-of-success assumptions and scenario weightings rather than into conventional earnings-based multiples.

The newly presented data package for RP2 provides greater granularity that these research houses can incorporate into such models, even if specific rating words or target-price revisions are not visible in open sources, and investors in the United States market will likely monitor any subsequent notes for shifts in the implied valuation range or risk perception.

The final first-in-human RP2 trial results formed the centerpiece of the latest update, with Replimune reporting that RP2 monotherapy achieved an objective response rate of 19.0% in 21 evaluable patients, including responses in uveal melanoma, esophagogastric adenocarcinoma, chordoma and mucoepidermoid carcinoma, while the combination of RP2 with nivolumab produced an objective response rate of 19.1% in 47 evaluable patients alongside a disease control rate of 48.9%, highlighting activity across a spectrum of advanced solid tumors.GlobeNewswire as of 05/31/2026

Durability has been a key question for oncolytic approaches, and the company reported that the median duration of response had not yet been reached for RP2 monotherapy, with a range of 11.5 to 27.3 or more months, while the median duration of response for the RP2 plus nivolumab arm was 22.1 months with a range of 2.8 to 35.2 or more months, which is likely to be scrutinized by clinicians and investors alike when assessing the potential of the program in competitive tumor settings.Barchart as of 05/31/2026

Beyond headline response and durability metrics, the company emphasized that tumor regression was seen not only in injected lesions but also in non-injected lesions, including in all three monotherapy responders who had non-injected sites, which supports the mechanistic thesis of a systemic immune response being triggered by the localized RP2 therapy and is an important mechanistic datapoint for immuno-oncology specialists.

From a safety perspective, Replimune reported that RP2 both alone and in combination with nivolumab was generally well tolerated, with no unexpected toxicities, no grade 4 or 5 treatment-related adverse events, and no meaningful increase in immune-related adverse events above the profile typically seen with nivolumab alone; the most frequent treatment-related adverse events were low-grade pyrexia, chills and fatigue, which the company described as consistent with systemic immune activation.GlobeNewswire as of 05/31/2026

Within uveal melanoma specifically, where Replimune has already moved into a randomized phase 2/3 trial, the pooled objective response rate across RP2 monotherapy and RP2 plus nivolumab was reported at 33.3%, a figure that will feed into expectations for that late-stage study and is likely to be an important focal point for any future updates from research houses covering the stock as they consider the addressable market and competitive landscape.

For investors tracking the name from Germany, Replimune Group is also accessible via trading venues such as Tradegate in euros, providing an additional access point outside US market hours, although liquidity and spreads can differ from the primary Nasdaq listing and should therefore be considered when comparing observable price moves between the United States and Europe.MarketBeat as of 05/29/2026

Conclusion

The combination of a notable share-price move on Nasdaq and the unveiling of final first-in-human RP2 data at ASCO 2026 has put Replimune Group back into the spotlight of the US biotechnology universe, with investors weighing the clinical signals against previous volatility in the stock.

While detailed rating and target-price changes from named research houses were not visible in open sources at the time of writing, the existence of an analyst consensus and the mechanistic data supporting systemic anti-tumor activity mean that the latest results are likely to be integrated into professional valuation models, particularly in indications such as uveal melanoma where a phase 2/3 trial is ongoing.

For equity investors following the story, the coming updates around RP2 and the broader RPx pipeline, as well as any subsequent funding or partnering steps, will be key in determining whether the recent price repricing in the United States can be sustained over a longer horizon.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.